Peptides DB
Research-centric peptide and protocol reference hub
Study 21 of 24Teriparatide (PTH 1-34) literatureOral diseases · Meta-analysis2026

Parathyroid Hormone for Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis.

Teriparatide may improve outcomes in medication-related osteonecrosis of the jaw, with an improvement rate of 90.1% in treated patients, but results should be interpreted cautiously due to study limitations.

Read at Oral diseasesAdd to compare

Where it sits

this study against the rest of the teriparatide (pth 1-34) corpus
1
Preclinical
18
Observational
0
Open-label
3
Randomised
2
Reviews · this one

Summary and findings

This systematic review and meta-analysis evaluated the impact of Teriparatide (TPTD) on medication-related osteonecrosis of the jaw (MRONJ) management. A total of 278 participants were included, with 161 receiving TPTD. Improvement in MRONJ was noted in 90.1% of the TPTD-treated group compared to 81.2% in the non-TPTD-treated group.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Odds ratio 5.81.2026

Abstract

The authors’ words, as Oral diseases supplied them

<h4>Background</h4>Medication-related osteonecrosis of the jaw (MRONJ) is a complication of antiresorptive therapy and can be refractory to treatment. Teriparatide (TPTD) has shown promise in the management of MRONJ. We aimed to comprehensively evaluate the impact of TPTD on MRONJ prevention and healing.<h4>Methods</h4>We systematically searched PubMed, Web of Science, Embase, Ovid, and LILACS in December 2024 to include studies that utilized TPTD/abaloparatide MRONJ management or prevention. Correlation analysis, meta-analysis, and meta-regression analysis were conducted. Quality assessment was performed using the Joanna Briggs Institute tool.<h4>Results</h4>All studies used TPTD for MRONJ management. Twenty-eight studies with 278 participants were included (TPTD n = 161; non-TPTD n = 117). MRONJ improvement was noted in 90.1% of the TPTD-treated group and 81.2% in the non-TPTD-treated group (odds ratio 5.81). The highest resolution rates were observed among patients who received a combination of surgical and non-surgical interventions for MRONJ in both groups.<h4>Conclusions</h4>Our results suggest a possible positive effect of TPTD on MRONJ resolution, and TPTD may have a synergistic effect when combined with surgical and non-surgical interventions. These results must be interpreted with caution since analyses were based on publications with a small number of cases and with variable outcome assessment reporting.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Teriparatide (PTH 1-34) corpus

BPhenotypic-Genotypic Discordance in Renal Tubular Acidosis with Hypokalemic Rhabdomyolysis and a TRAPPC2 Variant: A Case Reportbiorxiv-preprint · 2023 · n=1 · Serum potassium was 1.7 mmol/L during an acute episode.HumanDPerioperative Anabolic Osteoporosis Pharmacotherapy Is Associated With Lower Rates of Proximal Junctional Kyphosis After Adult Spinal Deformity Surgery: A Systematic Review and Meta-Analysis.Spine · 2026 · PJK odds reduced with anabolic pharmacotherapy, pooled OR 0.51, 95% CI 0.30 to 0.86, P=0.012, I2=0%, k=5.reviewCCombined Teriparatide and Exercise Effects on Diabetic Skeletal Muscle Ultrastructure.In vivo (Athens, Greece) · 2026 · Not reported in abstract.AnimalBReal-World Effectiveness of Osteoporosis Treatments on Bone Strength and the Impact of Sequential Anabolic Therapybiorxiv-preprint · 2026 · 39.5% increase in vertebral strength with Romo at 12 months, n=57, 95% CI [34.2, 44.7]HumanABioengineered acellular tissue engineered vessels versus autogenous fistulae for haemodialysis access: a multicentre, randomised, controlled, phase 3 trial.The Lancet. Digital health · 2026 · n=242 · Global relative patency of 1·17 (95% CI 1·04-1·31, p=0·0090).HumanCAscorbic acid mitigates oxidative structural degradation in bovine spermatozoa: a label-free quantitative phase microscopy study.Veterinary and animal science · 2026 · Not reported in abstract.Animal